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Chronic liver injury, resulted from different etiologies (e.g., virus infection, alcohol
abuse, nonalcoholic steatohepatitis (NASH) and cholestasis) can lead to liver fibrosis
characterized by the excess accumulation of extracellular matrix (ECM) proteins (e.g.,
type I collagen). Hepatic myofibroblasts that are activated upon liver injury are the key
producers of ECM proteins, contributing to both the initiation and progression of liver
fibrosis. Hepatic stellate cells (HSCs) and to a lesser extent, portal fibroblast, are believed
to be the precursor cells that give rise to hepatic myofibroblasts in response to liver
injury. Although, much progress has been made toward dissecting the lineage origin of
myofibroblasts, how these cells are activated and become functional producers of ECM
proteins remains incompletely understood. Activation of myofibroblasts is a complex
process that involves the interactions between parenchymal and non-parenchymal
cells, which drives the phenotypic change of HSCs from a quiescent stage to a
myofibroblastic and active phenotype. Accumulating evidence has suggested a critical
role of NADPH oxidase (NOX), a multi-component complex that catalyzes reactions from
molecular oxygen to reactive oxygen species (ROS), in the activation process of hepatic
myofibroblasts. NOX isoforms, including NOX1, NOX2 and NOX4, and NOX-derived
ROS, have all been implicated to regulate HSC activation and hepatocyte apoptosis,
both of which are essential steps for initiating liver fibrosis. This review highlights the
importance of NOX isoforms in hepatic myofibroblast activation and the progression
of liver fibrosis, and also discusses the therapeutic potential of targeting NOXs for liver
fibrosis and associated hepatic diseases.
Keywords: NADPH oxidase (NOX), liver fibrosis, myofibroblasts, reactive oxygen species (ROS), hepatic stellate
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INTRODUCTION
The main causes of hepatic fibrosis are chronic hepatitis B and C infection, autoimmune and
biliary diseases, alcoholic steatohepatitis (ASH) and, increasingly, nonalcoholic steatohepatitis
(NASH) (Bataller and Brenner, 2005). Liver fibrosis results from a sustained wound healing
process in response to chronic liver injuries, and is characterized by accumulation of excessive
extracellular matrix (ECM) proteins. Prolonged and excessive buildup of ECM proteins leads
to pronounced distortion of hepatic vascular architecture due to formation of the fibrous
scar, which promotes subsequent hepatocyte regeneration and hepatic endothelial dysfunction
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(Friedman, 2000). These processes facilitate the transition from
liver fibrosis to cirrhosis, which may ultimately progress to
more serious complications, such as portal hypertension due
to increased resistance to portal blood flow, spontaneous
bacterial peritonitis, and hepatic encephalopathy. Liver fibrosis
is reversible, whereas cirrhosis, the end-stage consequence of
fibrosis, is often irreversible and results in liver failure or the
development of hepatocellular carcinoma (HCC) and death
unless liver transplantation is done (Tsochatzis et al., 2014).
Thus, it is of utmost importance to investigate the molecular
and cellular mechanisms involved in the fibrogenic processes
in order to design novel therapeutic interventions for liver
fibrosis.
The major source of excessive ECM and fibrogenic mediators,
such as collagen, is myofibroblasts. Recent studies indicate
that the origin of myofibroblasts is liver intrinsic, and
activated hepatic stellate cells (HSCs) and portal fibroblasts
are believed to be the main precursors that give rise to
hepatic myofibroblasts (Brenner et al., 2012). Upon liver injury,
HSCs and portal fibroblasts undergo dramatic phonotypical
changes by acquiring profibrogenic properties. In the normal
liver, quiescent HSCs positive for adipocytes markers (PPARγ,
SREBP-1c, and leptin) are the major cell type responsible for
vitamin A storage (Bataller and Brenner, 2005). Upon activation
by fibrogenic cytokines such as TGF-β1, angiotensin II, and
leptin, quiescent HSCs trans-differentiate into myofibroblasts,
possessing the properties of contractile, proinflammatory,
and profibrogenic (Friedman, 2000). Activated HSCs express
myogenic markers, such as α smooth muscle actin, c-
myc, and myocyte enhancer factor–2 (Bataller and Brenner,
2005).
Accumulating clinical and pre-clinical data suggest that
chronic liver injury results in the generation of oxidative
stress, which disrupts lipids, proteins and DNA, induces
necrosis/apoptosis of hepatocytes and amplifies the inflammatory
response. Moreover, reactive oxygen species (ROS) mediate the
progression of hepatic fibrosis by stimulating the production
of profibrogenic mediators from Kupffer cells and circulating
inflammatory cells and by directly activating HSCs to induce
their trans-differentiation into myofibroblasts (Sánchez-Valle
et al., 2012). Emerging evidence indicate that the nicotinamide
adenine dinucleotide phosphate (NADPH) oxidases (NOXs) are
sources of ROS, which play crucial roles in the progression
of hepatic fibrosis (Aoyama et al., 2012; Paik et al., 2014).
Seven NOXs isoforms have been identified in mammals so far.
The major NOX isoforms expressed in the liver are NOX1,
NOX2, and NOX4. NOX2 was the first discovered NOX in
phagocytes, which plays important role in inflammation and
host immune defense. HSCs and hepatocytes express NOX1,
NOX2, and NOX4. It becomes increasingly clear that NOX-
dependent ROS production is not limited to phagocytes because
NOX enzymes are widely expressed and active in many
different cell types from varies of tissues and organs. This
review will focus on summarizing the roles of NOX isoforms
that are distinctly expressed in different cell types in the
liver.
NADPH OXIDASES
ROS are defined as oxygen radicals, including reactive molecules,
such as peroxide, superoxide, hydroxide, and singlet oxygen.
In physiological conditions, ROS are generated during normal
oxygen metabolism and play important roles in maintaining
cellular homeostasis by orchestrating host defense, cell growth
and signaling. However, ROS can also rapidly accumulate in
large quantities during oxidative stress when cells encounter
either endogenous or exogenous challenges. This, if not properly
controlled, might lead to adverse cellular events, including
irreversible cellular damage and death which may ultimately
results in tissue damage and organ dysfunction (Devasagayam
et al., 2004). ROS mediated oxidative stress is strongly associated
with varieties of human diseases, including Parkinson’s (Smeyne
and Smeyne, 2013), Alzheimer (Aliev et al., 2014), cardiovascular
(Robert and Robert, 2014), immunological (De Deken et al.,
2014), pulmonary (Wong et al., 2013), renal (Ozbek, 2012), as
well as liver diseases (Jaeschke, 2011).
In chronic liver diseases, pathological insults, such as
ischemia-reperfusion, cholestasis or drug toxicity, induce
hepatocyte death, which activates immune cells and
promotes HSC transdifferentiation into collagen-producing
myofibroblasts, which ultimately drives the development of
hepatic fibrosis and cirrhosis. ROS accumulation in hepatocytes
can cause cell death, which release damage-associated molecular
patterns (DAMPs) that stimulates liver resident Kupffer cells
and newly recruited immune cells to produce profibrogenic
mediators. ROS is vital for HSC activation, resulting in the
initiation of fibrosis. In the liver, several cellular machineries
can generate ROS, including the mitochondrial respiratory
chain, cytochrome P450 (CYP) family members, peroxisomes,
xanthine oxidase, and NADPH oxidases. NADPH oxidase that
produces ROS was first discovered in phagocytes, referred as
gp91phox (also known as NOX2), and serves as an important
inflammatory mediator against invading bacteria. Recently,
other NOX2 like molecules have been identified in various
tissues. Due to the sequential and functional similarities of these
enzymes to NOX2, these enzymes, together with NOX2 are
collectively referred to as the NOX family. The NOX family
genes encode proteins responsible for a transmembrane electron
transport chain containing a flavocytochrome b, which transfers
electrons donated by NADPH across biological membranes to
form superoxide (O−2 ) and hydrogen peroxide (H2O2) from
molecular oxygen (Cross and Segal, 2004). Seven NOX family
members have been identified so far, including NOX1, NOX2
(formerly known as gp91phox), NOX3, NOX4, NOX5, and dual
oxidase Duox proteins (DUOX1 and DUOX2).
The phagocytic NOX (NOX2) core enzyme comprises several
different subunits that interact with each other to form an active
enzyme complex, including NOX2 (gp91phox), p40phox (PHOX
for phagocyte oxidase), p47phox, p67phox, p22phox, Rac2, and
Rap1A, which is responsible for superoxide production upon
agonist stimulation. In the resting stage, two integral membrane
proteins—gp91phox and p22phox, form a large heterodimeric
subunit flavocytochrome b558 (cyt b558). Three of the regulatory
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proteins, p40phox, p47phox, and p67phox form a complex in the
cytosol (Groemping and Rittinger, 2005; Sumimoto et al., 2005).
Upon stimulation (e.g., exposure of cells to microorganisms
or inflammatory mediators), p40phox is highly phosphorylated,
resulting in the entire cytosolic complex translocation to plasma
membrane and association with flavocytochrome b558. The
whole NOX complex activation also requires the association of
two low-molecular-weight guanine nucleotide-binding proteins,
Rac2 GTPase and Rap1A (Diebold and Bokoch, 2001). Then
the activated complex transfers electrons from the cytosolic
NADPH to oxygen on the luminal or extracellular region (Koga
et al., 1999). The expression of NOX2 is induced by interferon-γ
(IFN-γ) through a transcription factor protein complex, called
hematopoiesis-associated factor (HAF1), which is comprised
of PU.1, interferon regulatory factor 1 (IRF-1), and interferon
consensus sequence-binding protein (ICSBP) (Eklund et al.,
1998).
NOX1 is identified as the first homolog of NOX2, and
shares 60% amino-acid identity with NOX2 (Suh et al., 1999).
NOX1 is widely expressed in many cell types, such as vascular
smooth muscle cells (VSMCs), endothelial cells, astrocytes, and
microglia. In liver, NOX1 is expressed in HSCs, ECs, and
hepatocytes. However, the subcellular localization of NOX1
remains nebulous. It was suggested that NOX1 is a plasma
membrane protein, and potentially resides in caveolin 1-
containing lipid rafts (Hilenski et al., 2004; Zuo et al., 2005).
Similar to NOX2, the activation of NOX1 also requires regulatory
subunits, known as NOX organizer 1 (NOXO1) and NOX
activator 1 (NOXA1), which are homologs of p47phox and
p67phox, respectively (Bánfi et al., 2003; Cheng and Lambeth,
2004). In addition, p22phox and Rac GTPase are also required for
NOX1 activation. Expression of NOX1 is also highly regulated.
Its mRNA is induced by the growth factors including platelet-
derived growth factor (PDGF), and angiotensin and phorbol
esters (Suh et al., 1999; Lassègue et al., 2001).
NOX4, which is first discovered in kidney, shares 39%
sequence homology with NOX2 (Geiszt et al., 2000). Its activity
requires direct interaction with p22phox, but independent of the
interactionwith any cytosolic regulatory subunits (Ambasta et al.,
2004).Moreover, Poldip2, a polymerase delta-interacting protein,
has been shown to be associated with p22phox, which ultimately
increases NOX4 enzymatic activity in VSMCs (Lyle et al., 2009).
Similar to NOX1, NOX4 expression can also be regulated by
angiotensin II. Moreover, TGFβ is also a potent regulator of
NOX4 mRNA (Sturrock et al., 2006; Bondi et al., 2010).
ORIGINS AND ACTIVATION OF HEPATIC
MYOFIBROBLASTS
Chronic liver injury of all etiologies can promote liver fibrosis,
a wound healing process whose hallmark is the formation
of fibrous scar constituted by ECM. The main producer of
extracellular matrix proteins in the liver is myofibroblast, a
terminally differentiated cell type that plays a critical role
in wound healing and connective tissue remodeling. Not
only possessing the ECM synthesizing features of fibroblasts,
myofibroblast also has the contractile functions similar to
the smooth muscle cells (Hinz et al., 2012). Under the self-
limiting and homeostatic tissue repair processes, such as wound
healing, myofibroblasts are induced and differentiated from their
precursors, migrate to the site of injury, function to produce
ECM proteins to contract the wound, and finally undergo
apoptosis once injury is resolved. However, these processes
can become uncontrolled when the myofibroblasts activities
become excessive and persist due to the inability to undergo
apoptosis, for example. This will lead to overwhelming ECM
deposition, resulting in fibrosis and eventually cirrhosis (Watsky
et al., 2010). In addition to the normal tissue repair and
wound healing responses, myofibroblasts also contribute to
regeneration, inflammation, angiogenesis, and stromal reaction
during tumorigenesis. Although, myofibroblasts differ from
fibroblasts by their ability of the former to de novo synthesize
of α-smooth muscle actin (α-SMA), this is not an absolute
requirement to define a cell as myofibroblast. Instead, the most
reliable features of myofibroblasts are secretion of extracellular
matrix, development of adhesion structures, and formation
of contractile bundles (Hinz, 2010). Several novel markers
of myofibroblasts, such as endosialin for tumor-associated
myofibroblasts (Christian et al., 2008), P311 for hypertrophic
scar myofibroblasts (Tan et al., 2010), and integrin α11β1 for
human corneal myofibroblasts (Carracedo et al., 2010), have been
recently identified. However, none of these markers are specific
for myofibroblasts, and they play distinct roles in various types of
fibroblasts, therefore affecting myofibroblasts differentiation in a
tissue- and context- dependentmanner. Nonetheless, reliable and
unique markers for myofibroblasts remain to be defined.
Myofibroblasts are absent in healthy liver, but they are
induced and activated from their precursor cells in response
to hepatic injury. Although, the origin of myofibroblasts is
yet unclear, three possible sources of myofibroblasts precursors
in the liver have been proposed. The first possible source
is the group of resident cells from the mesodermal origin
that can potentially become myofibroblasts. This includes
HSCs, portal fibroblasts, smooth muscle cells, and fibroblast
around the central veins, which are different from hepatocytes,
Kupffer cells, and sinusoidal endothelial cells. The second
group of possible precursors of myofibroblasts are hepatocytes,
cholangiocytes, and endothelial cells that can undergo epithelial
or endothelial mesenchymal transition (EMT). However, several
fate tracing and genetic labeling studies argued that hepatocytes
or cholangiocytes did not undergo EMT in liver fibrosis models
(Humphreys et al., 2010; Scholten et al., 2010; Taura et al.,
2010). As for renal fibrosis, recent two studies argued that
renal epithelial cells can undergo EMT, relaying signals to
the interstitium to promote myofibroblast differentiation and
fibrogenesis rather than directly giving rise to myofibroblasts
population (Grande et al., 2015; Lovisa et al., 2015). Finally,
bone marrow (BM)-derived cells consisting of fibrocytes and
circulating mesenchymal cells can migrate into fibrotic liver
tissue, transform into myofibroblasts and may contribute in
the progression of liver fibrosis (Russo et al., 2006). Thus,
these cells could also be possible precursors of myofibroblasts.
However, a recent study using bone marrow (BM) chimeric mice
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reconstituted from transgenic collagen reporter mice suggested
that BM cells had negligible contribution in collagen production
during hepatic fibrosis (Higashiyama et al., 2009).
Among different mesenchymal cell types, the vitamin A-
containing lipocytes (HSCs) capable of producing type III
collagen was the first identified myofibroblast precursor in the
liver (Kent et al., 1976). Since then, much focus has been put on
HSCs to identify the origin of myofibroblasts. Upon liver injury,
HSCs are activated, and converted from quiescent vitamin-A rich
cells to proliferative, fibrogenic, and contractile myofibroblasts
(Friedman, 2008). HSCs are regarded as the “warehouse”
of retinoid droplets that exhibit blue-green autofluorescence
when excited by UV light. However, cells that are absent of
retinoid droplets are distinct from HSCs, which undergo a
PDGF-mediated conversion into myofibroblasts (Kinnman et al.,
2003). These cells are thought to be portal fibroblasts that are
accumulated around bile ducts, and might play a critical role
in the early stage of bile duct ligation (BDL) induced fibrosis
(Tuchweber et al., 1996). Moreover, liver fibrosis seems to
develop predominantly from the portal area and progress from
there, irrespectively of the underlying etiology. Therefore the role
of portal fibroblasts in the development of fibrosis may be more
important than generally assumed.
NOXS IN HSC ACTIVATION
Upon liver injury, quiescent HSC become activated. The
activation process is characterized by the loss of vitamin-A
containing droplets, de novo synthesis of a-SMA, collagen and
ECM proteins, and increased contractile and cell survival. The
activation of HSC is a complex process, which involves the
contribution of extracellular stimuli and different cell types,
including parenchymal cells, immune cells. NOX proteins and
NOX-derived ROS play a key role during HSC activation
(Figure 1). ROS are produced in defined cellular compartments,
but diffuse throughout the cell (e.g., superoxide) or across the
plasmamembranes (e.g., H2O2). ROS, when present at low levels,
could serve as secondary messengers in response to a variety of
cellular stimuli. For instance, it has been shown that low amount
of hydrogen peroxide (H2O2) can act as second messenger that
plays a critical role in the initiation and amplification of signaling
during lymphocyte activation (Reth, 2002). In contrast, high level
of ROS can be toxic and may lead to cell death. Although, low
levels of ROS promote HSC to produce collagen and proliferate,
while high-level toxic amount of ROS can induce death of HSCs
(Novo et al., 2006).
NOXs are highly upregulated in patients with organ fibrosis,
such as heart, lung, kidney, and pancreas. In consistence with
their role in human fibrosis, NOX-derived ROS is also essential
for multiple organ fibrosis in mice (Paik et al., 2006). In addition,
during HSC activation, NOX mediates a number of fibrogenic
responses induced by different agonists, including Ang II, PDGF,
leptin, and TGFβ. Moreover, phagocytosis of apoptotic bodies by
HSC leads to NOX activation and procollagen α1 (I) expression
(Zhan et al., 2006). The expression of NOX isoforms is different
among different types of liver resident cells. Kupffer cells only
express phagocytic NOX2, whereas hepatocytes and HSC express
FIGURE 1 | The role of NOXs in myofibroblasts activation. The
interactions between hepatocytes, Kupffer cells and HSCs promotes
myofibroblast activation. Various NOX isoforms expressed in different cell
types in the liver play crucial roles during this process. After exposure to
hepatic insults, such as ischaemia/reperfusion (IR) injuries, alcohol abuse, viral
infection, hyper-nutrition, and cholestasis, ROS is produced through NOXs in
hepatocytes. Increased oxidative stress also induces hepatocyte
apoptosis/necrosis, resulting in release of DAMPs that activate Kupffer cells.
Injured hepatocytes and activated Kupffer cells secrete proinflammatory and
profibrogenic cytokine TGFβ, which promotes the differentiation of HSCs into
myofibroblasts (see text for further details).
various NOX isoforms, including phagocytic NOX2 and non-
phagocytic NOX1, NOX4, DUOX1, and DUOX2. Endothelial
cells mainly express NOX1, NOX2, and NOX4. Upon liver
injury, NOX isoforms in HSC are strongly upregulated when
quiescent HSC become activatedmyofibroblasts (Paik et al., 2011;
Aoyama et al., 2012). HSCs can also fine-tune ROS production by
expressing the regulatory subunits of NOX complexes, including
p22phox, p40phox, p47phox, p67phox, NOXO1, NOXOA1, and Rac1.
It has been shown that the p47phox regulatory subunit is induced
in HSCs activated upon BDL-mediated fibrosis (DeMinicis et al.,
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2010). At resting stage, human HSCs express low levels of both
catalytic and regulatory NOX components, including NOX1,
NOX2, and p47phox. However, these NOX subunits are highly
upregulated in HSCs from patients with fibrotic liver diseases
(Bataller et al., 2003). Moreover, NOX1 and NOX4 protein levels
were increased in human livers with cirrhosis compared with
normal controls (Lan et al., 2015).
NOX4 IN HSCS
A complex network involving paracrine/autocrine signals in
parenchymal and nonparenchymal cells is required for HSCs
activation and differentiation into myofibroblasts. Accumulating
evidence has suggested that NOXs are the key mediators
in HSC activation, which promotes hepatic fibrosis. TGFβ
is the most potent regulator promoting collagen production
and α-SMA expression in myofibroblasts from various organs,
including liver (Gressner et al., 2002), kidney (Desmoulière
et al., 2003), lung (Hardie et al., 2009), and heart (Kuwahara
et al., 2002). During the initiation and progression of liver
fibrosis, TGFβ plays a crucial role in regulating HSC activation,
as well as inducing hepatocyte apoptosis, which leads to the
secretion of cytokines, chemokines and microparticles that
are critical for HSC and Kupffer cell activation. A number
of studies have shown that NOX4 is essential for TGFβ-
induced myofibroblast activation and fibrogenic responses such
as collagen production in different organs, including lung
(Hecker et al., 2009), kidney (Bondi et al., 2010), heart (Cucoranu
et al., 2005; Chan et al., 2013), and prostate (Sampson et al.,
2011). Moreover, although NOX4 can be induced by TGFβ
in several different organs (Cucoranu et al., 2005; Sturrock
et al., 2006; Bondi et al., 2010; Boudreau et al., 2012), the
mechanism involved is controversial among different organs.
In kidney and lung myofibroblasts, TGFβ induces NOX4
expression and ROS generation through the classical Smad2/3
pathway (Sturrock et al., 2006; Bondi et al., 2010), whereas
NOX4 ugregulation is upstream of Smad2/3 activation in
cardiac myofibroblasts (Cucoranu et al., 2005). In liver fibrosis,
TGFβ induces NOX activity and ROS production during HSC
activation, which plays key role in hepatic myofibroblasts
activation (Proell et al., 2007). In BDL- or CCl4-mediated
liver fibrosis, NOX4 expression and its activity are upregulated
via a TGFβ-Smad3 dependent manner in HSCs (Jiang et al.,
2012; Sancho et al., 2012). In addition, NOX4 expression
correlates with the fibrotic scores in patients with hepatitis C
virus infection or NASH (Sancho et al., 2012; Bettaieb et al.,
2015). ROS production and the expression of fibrogenic markers
are dramatically reduced in HSCs deficient in NOX4 (Jiang
et al., 2012). Moreover, experiments using siRNA against NOX4
attenuated HSC activation, and more importantly, knocking
downNOX4 in activatedmyofibroblasts could reverse the fibrotic
phenotypes. Knocking down NOX4 in activated HSCs decreased
the expression a-SMA and collagen production with no influence
on TGFβ1 expression and phosphorylation of Smad2/3. These
indicate that NOX4 activation and the following ROS production
are downstream of TGFβ-Smad2/3 signaling pathway (Sancho
et al., 2012).
Patients with hepatic fibrosis as a result of various chronic liver
injuries, including viral infection, toxin, metabolic disorders,
alcohol abuse, and cholestasis, have a breach in gut barrier
function. This leads to compromised intestinal permeability that
allows the entry of bacteria-derived components (e.g., LPS and
CpG-containing DNAs through portal circulation and eventually
into the liver, where they activates liver immune cells via
acting on toll-like receptors (TLRs) (Seki and Brenner, 2008;
Yang and Seki, 2012). TLRs are a group of pattern recognition
receptors that recognize their cognate ligands with as either
pathogen-associated molecular patterns (PAMPs) or DAMPs.
Although, both murine and human HSCs express multiple
TLRs (Wang et al., 2009), they respond poorly to TLR ligands,
such as Gram-positive bacterial products peptidoglycan (PGN)
and lipoteichoic acid (LTA) (Paik et al., 2006). Upon ligand
engagement, TLRs are activated and transduce signals through
downstream adaptor molecules MyD88 and TRIF to induce
the expression of proinflammatory cytokines and chemokines.
These inflammatory mediators then recruit KCs and circulating
monocytes/macrophages, which produce TGFβ1 to drive the
differentiation of HSC into myofibroblast (Seki and Brenner,
2008; Aoyama et al., 2010). Although, the LPS-TLR4 axis is
crucial for hepatic fibrogenesis and liver fibrosis is dramatically
attenuated in germ-free mice (Seki et al., 2007), the roles
of NOX and ROS have not been extensively studied in the
context of regulating LPS-TLR4 mediated inflammatory or
fibrogenic responses in HSCs. In macrophages, NOX inhibitor
DPI or siRNA against p22phox significantly decreased LPS-TLR4-
mediated activation of endoplasmic reticulum (ER)-stress sensor
kinase IRE1α and its downstream target, the transcription factor
XBP1 (Martinon et al., 2010). Moreover, it has been shown that
the C-terminal domains of NOX4 and TLR4 directly interact with
each other in HEK293T cells (Park et al., 2004). Consistently,
in human aortic endothelial cell (HAECs), overexpression of
the C-terminal region of NOX4 inhibited nuclear factor-kappaB
(NF- κB) activation in response to LPS. NOX4 downregulation
using siRNA resulted in reduced ROS production and less
expression of adhesion molecule (ICAM-1) and chemokines
such as CXCL8 and MCP-1 in response to LPS (Park et al.,
2006). Therefore, NOX4 and NOX4-mediated ROS generation
may regulate LPS induced NF-κB activation and its downstream
signaling pathway in HSC activation and profibrogenic effects of
myofibroblasts.
NOX1/NOX2 IN HSCS
In addition to the TGFβ-NOX4 axis-mediated activation of
HSC and expression of fibrogenic factors, other NOX isoforms,
including NOX1, NOX2, and NOX2 regulatory subunit p47phox,
are also reported to orchestrate the progression of hepatic
fibrosis (Aram et al., 2009; Jiang et al., 2010; Paik et al.,
2011). p47phox−/− mouse was the first genetic model of NOX
inhibition in the study of HSC function in liver fibrosis. After
BDL-induced liver injury, p47phox−/− mice showed attenuated
liver injury and fibrosis compared with WT mice. HSCs
produce more type I collagen and TGFβ when treated with
Angiotensin II (Ang II) (Yoshiji et al., 2001). Ang II also
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stimulates ROS production, and activates intracellular signaling
pathways involving PKC, PI3K-Akt, MAPKs, ERK, and c-Jun,
which presumably promotes HSC migration and proliferation.
Consistent with this notion, HSC isolated from p47phox−/− mice
had reduced cell motility and expansion capacity, and displayed
a reduced fibrogenic response to Ang II (Bataller et al., 2003).
Although the detailed molecular mechanism underlying Ang II-
induced NOX activation and ROS production is still unclear,
studies have indicated that Ang II induces ROS production
through two consecutive events in vascular smooth muscle
cells: the first event, which occurs within 30 s after Ang II
stimulation, is dependent on PKC-mediated phosphorylation
of p47phox. Phosphorylated p47phox then translocates to the
membrane where it binds to and facilitates the activation of
NOX1 and/or NOX2. The second event that leads to sustained
NOX activation and the following ROS production induced
by Ang II (peaked at 30min) requires the activation of Rac
GTPase. Ang II-mediated Rac activation is PI3K, EGFR, and
c-Src dependent (Seshiah et al., 2002). In order to keep the
prolonged signal induced by Ang II, the expression levels of
NADPH catalytic subunits, as well as the regulatory subunits
p47phox and p22phox are also upregualted during Ang II
stimulation (Fukui et al., 1997; Lassègue et al., 2001; Touyz et al.,
2002). Similarly in HSCs, the mRNA levels of both NOX1 and
NOX4 are increased upon Ang II treatment (Aoyama et al.,
2012).
Proliferation of HSCs is a prerequisite that mediates the
proper function of HSC-derived myofibroblasts and fibrogenic
response in general. It has been suggested that NOX1 is
crucial for promoting HSC proliferation and ROS production
in bile duct ligated mouse liver. The underlying molecular
mechanism is proposed to involve oxidation and inactivation
of phosphatase and tensin homolog (PTEN), leading to the
activation of AKT/FOXO4/p27(kip) signaling pathway that
promotes HSC proliferation and fibrogenesis following BDL-
induced liver injury (Cui et al., 2011). Platelet-derived growth
factor (PDGF) is considered the most potent mitogen that
promotes HSC proliferation (Pinzani et al., 1989). It has
been shown that NOXs play a crucial role in this process
(Adachi et al., 2005). PDGF induces HSC proliferation through
ROS production, and NOX inhibitor (DPI) or p38 MAPK
inhibitor suppressed PDGF-induced ROS production and HSC
proliferation (Adachi et al., 2005). Similarly, PDGF stimulates
NOX-dependent proliferation of activated pancreatic stellate
cells (PaSCs) in chronic alcoholic pancreatitis/fibrosis (Hu
et al., 2007). Mechanistically, PDGF stimulation promotes NOX1
expression and ROS production. In line with this, NOX1
is critical in PDGF stimulated vascular hypertrophy through
activation of PKCδ (Fan et al., 2005) and inducing transcription
factor (ATF)-1 (Katsuyama et al., 2005). Additionally, it
has been shown that the transcription factor AP1 binding
site is critical for the promoter activity of NOX1 (Cevik
et al., 2008). Recently, it has also been shown NOX1/NOX4
inhibitor suppressed PDGF mediated ROS production and
proliferative gene expression in primary mouse HSCs (Lan et al.,
2015).
NOXS IN HEPATOCYTES
Hepatocytes injury and death are important triggers of
myofibroblasts activation. Dying hepatocyte can release DAMPs
that induce the secretion of cytokines and chemokines from
KCs/macrophage that eventually results in HSC activation and
liver fibrosis. TGFβ1, secreted by active KCs/macrophage upon
liver injury, can promote hepatocyte apoptosis (Oberhammer
et al., 1992). The classical TGFβ mediated signaling pathway
requires the binding of TGFβ1 to the TGFβ receptor (TGFβRI
and II), leading to the phosphorylation and activation of
Smad2/Smad3. Smad2/3 then interact with Smad4 to form
an active Smad complex that enters the nucleus and binds
to the promoter regions of TGFβ target genes to initiate
their transcription. NOX4 is one of the TGFβ target genes.
A key finding is that the expression of NOX4 is increased
in NASH patients compared with healthy controls (Bettaieb
et al., 2015). In hepatocytes, NOX4 expression is induced
by TGFβ, and the activity of NOX4 is crucial for TGFβ
mediated apoptosis of hepatocytes (Carmona-Cuenca et al.,
2008). For instance, knocking downNOX4 in human hepatocytes
cell lines (HepG2 and Hep3B) resulted in impaired NOX
activity, caspase activation and cell death induced by TGFβ1
(Carmona-Cuenca et al., 2008). In rat fetal hepatocytes, TGFβ1
induces apoptosis through upregulating NOX4-mediated ROS
production, followed by down-regulation of pro-survival protein
Bcl-xL, which ultimately results in the loss of mitochondrial
membrane potential and initiation of cytochrome C release
(Herrera et al., 2001). Additionally, TGFβ1-induced NOX4
activity also increases the levels of pro-apoptotic proteins
BIM and BMF (Ramjaun et al., 2007; Caja et al., 2009), and
thus further amplifies apoptotic signals. NOX4-derived ROS
regulates the transcription of Bcl-xL and Bmf, whereas its
regulation of BIM occurs post-transcriptionally (Caja et al.,
2009). Moreover, EGF blocks TGFβ-induced NOX4 expression
and hepatocytes death in a MEK/ERK and PI3K/Akt dependent
manner (Carmona-Cuenca et al., 2006). Interestingly, NOX4
not only contributes to TGFβ-mediated apoptosis, but also
to death ligand (such as FasL or TNFα/actinomycin D)-
induced hepatocyte apoptosis (Jiang et al., 2012). Hepatocyte-
specific deletion of NOX4 reduced oxidative stress, lipid
peroxidation and liver fibrosis in mice (Bettaieb et al., 2015).
NOX4 was suggested to reduce the activity of the phosphatase
PP1C, leading to prolonged activation of key stress signaling
PKR/PERK pathway (Bettaieb et al., 2015). Therefore, NOX4
promotes myofibroblasts activation and hepatic fibrosis through
at least two distinct mechanisms: (1) directly facilitating
TGFβ-induced HSC activation and production of profibrogenic
targets, (2) indirectly promoting TGFβ or death ligand-
induced hepatocytes apoptosis, which contributes to the
production of cytokines, chemokines, and microparticles that
leads to HSC activation (Aoyama et al., 2012; Jiang et al.,
2012).
Different from other NOX family proteins, the activity
of NOX4 mainly depends on its expression levels, and not
on agonist-induced assembly of a complex (Serrander et al.,
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2007). NOX4 predominantly mediates H2O2 production instead
of superoxide (Martyn et al., 2006; Serrander et al., 2007).
Potentially, H2O2 generated by NOX4 may contribute to the
activation of certain protein tyrosine kinases that play crucial
roles in TGFβ downstream signaling pathways (Bae et al., 2011).
Hepatocytes and sinusoidal endothelial cells also express all of
the components for NOX1 and NOX2 H (Jiang and Török,
2014). Owever, the mechanisms underlying NOX1/2 enzyme
activation in these cells and their roles in regulating fibrosis and
myofibroblasts activation remain largely unknown.
TARGETING HEPATIC FIBROSIS BY
INHIBITING NOXS
Fibrosis is an intrinsic wound healing response that helps to
maintain organ integrity upon severe tissue damage. However,
fibrosis may also become problematic when persistent injury
and sustained inflammation occurs. Unresolved liver fibrosis
leads to accumulation of excessive ECM proteins and scarring,
which eventually progresses to cirrhosis and HCC. As the
key cells that produce fibrotic ECM and other fibrogenic
components, hepatic myofibroblasts, and their products are
considered primary targets for antifibrotic therapies (Schuppan
and Kim, 2013; Tsochatzis et al., 2014). However, there is
still no FDA-approved drug for the treatment of liver fibrosis.
Accumulating evidence have suggested the critical pathogenic
effects of oxidative stress in the development of liver fibrosis,
therapies that target ROS using antioxidants have therefore been
applied in pre-clinical models of liver diseases. For example, a
natural antioxidant Pyrroloquinoline-quinone (PQQ) found in
human foods, suppresses oxidative stress, and liver fibrogenesis
in mice with attenuated liver damage, hepatic inflammation and
activation of HSCs (Jia et al., 2015). Similarly, Silybin, an extract
of silymarin with antioxidant and anti-inflammatory properties,
has been shown to be hepatoprotective in rat livers with
secondary biliary cirrhosis (Serviddio et al., 2014). Additionally, a
recent study suggested that blocking chloride channels prevented
the increase of intracellular superoxide anion radicals, leading
to attenuated activation of HSCs (den Hartog et al., 2014).
However, it should also be noted that several antioxidants have
failed in clinical trials to demonstrate their efficacy in antifibrotic
response, such as polyenylphosphatidylcholine in alcoholic liver
disease (Lieber et al., 2003), and Ursodeoxycholic acid (UDCA)
and vitamin E in NASH (Lindor et al., 2004; Sanyal et al., 2010).
Given the vital role of NOX and NOX-derived ROS in
hepatic fibrogenesis, the use of novel pharmacological NOX
inhibitors to treat patients with chronic liver disease is being
considered as the most promising antifibrotic therapeutics.
However, historical NOX inhibitors, such as apocynin and
diphenylene iodonium (DPI), do not specifically target NOX-
derived ROS and are not isoform specialized. Until recently,
GenKyoTex (Geneva, Switzerland) has developed a first-in-class
small molecule NOX1/NOX4 dual inhibitor (GKT137831), with
little affinity for Nox2 isoform (Laleu et al., 2010). Inhibition
of NOX1/NOX4 using GKT137831 attenuated CCl4 or BDL-
induced ROS production and hepatic fibrosis in mice (Aoyama
et al., 2012; Jiang et al., 2012; Lan et al., 2015). Mechanistically,
GKT137831 suppressed profibrotic gene expression and ROS
production in HSCs (Aoyama et al., 2012; Lan et al., 2015),
and also decreased hepatocyte apoptosis (Jiang et al., 2012).
GenKyoTex is finalizing Phase II clinical study, and GKT137831
displayed an excellent safety profile and statistically significant
reduction in both liver enzyme and inflammatory marker levels.
Together with results from pre-clinical animal models of various
fibrotic disorders, NOX inhibition shows strong potential as
an effective treatment for hepatic fibrosis. However, chronic
liver diseases of different etiologies may require specific and/or
combination antifibrotic treatment approaches, based on the
fact that the crosstalk between different cell types is critical for
myofibroblasts activation. Future, studies on the components and
functions of specific NOX isoforms in specific cell types and
specific liver diseases will provide deeper insights for designing
more specific and potent NOX inhibitors for the treatment of
hepatic fibrosis.
CONCLUSIONS
Oxidative stress and inflammation are considered as the main
cause of chronic liver diseases. Multiple lines of evidence
indicate that NOX-generated ROS plays a pivotal role in the
pathogenesis of liver fibrosis. A number of NOX isoforms,
including NOX1, NOX2, and NOX4 are involved in the initiation
of myofibroblasts activation and progression hepatic fibrosis.
However, the intracellular pathways and molecular mechanisms
involved in the role of NOX isoforms in specific cell types
remain largely unknown. Targeting specific NOX isoforms with
specific inhibitors, such as NOX1 and/or NOX4 to prevent
HSC activation and protect hepatocyte injury may be promising
to treat liver fibrosis, although future work is needed to fully
confirm the clinical safety of these compounds. Moreover, the
knowledge of molecular pathways involved in NOX-mediated
myofibroblasts activation and fibrogenesis can provide new
insights for developing novel anti-fibrotic treatments.
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